Johnson & Johnson Reports P-III (Vivacity-MG3) Trial Data of Nipocalimab for Generalized Myasthenia Gravis
Shots:
- J&J has reported additional findings from P-III (Vivacity-MG3) trial & ongoing OLE assessing nipocalimab + SoC (30mg/kg, IV loading dose followed by 15mg/kg, Q2W) vs PBO in anti-AChR+, anti-MuSK+ & anti-LRP4+ adults (n=153) with gMG
- Trial showed a -4.9 QMG score improvement over 22 & 24wks. & pts were 4x more likely to sustain improvement at 20wks.; 36.4% vs 10.5% maintained >75% of the study with improved QMG scores
- After 60wks. in OLE, nipocalimab showed a mean MG-ADL change of -5.64 for treatment arm & -6.01 for those switching from PBO, with 45% Antibody+ pts reduced or stopped steroids, with prednisone dosage decreasing from 23 to 10mg/day; data was presented at AAN 2025
Ref: Johnson & Johnson | Image: Johnson & Johnson
Related News:- Johnson & Johnson Receives the EC’s Approval for SC Rybrevant to Treat Advanced EGFR-Mutated NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Ridhi is an avid secondary researcher who follows trends in the biopharmaceutical and healthcare sectors to curate engaging content for the global audience. She works as a news editor at PharmaShots and loves to read books and explore new destinations.
